CJC-1295 / Ipamorelin

Explore a coordinated peptide protocol centered on the body’s growth-hormone signaling pathway.

How it is intended to work: CJC-1295 is designed to mimic growth-hormone-releasing hormone, while ipamorelin is designed to stimulate growth-hormone release through a different receptor. The combination is targeted for goals such as recovery, sleep quality, lean mass, or fat reduction.

What to expect: A clinician should review cancer history, diabetes risk, swelling, joint symptoms, sleep apnea, pregnancy, and other medications before considering treatment. Monitoring may include glucose and IGF-1. Stop and contact the care team for a significant reaction or new concerning symptoms.